Seeking Clues to Collegium Pharmaceutical (COLL) Q4 Earnings? A Peek Into Wall Street Projections for Key Metrics

Core Viewpoint - Analysts project that Collegium Pharmaceutical (COLL) will report quarterly earnings of $1.54 per share, a decline of 2.5% year over year, with revenues expected to reach$ 180.4 million, an increase of 20.5% from the same quarter last year [1]. Earnings Estimates - Over the past 30 days, the consensus EPS estimate has been adjusted downward by 2.9%, indicating a reassessment by covering analysts [2]. - Changes in earnings estimates are crucial for predicting investor reactions to the stock, as empirical research shows a strong correlation between earnings estimate revisions and short-term stock price performance [3]. Key Metrics Projections - Analysts estimate 'Total product revenues- Belbuca' at $53.96 million, reflecting a year-over-year increase of 9.4% [5]. - 'Total product revenues- Xtampza ER' is forecasted to reach$ 49.96 million, indicating a 6.5% year-over-year increase [5]. - The consensus estimate for 'Total product revenues- Symproic' is $3.92 million, showing a decline of 22.9% from the prior-year quarter [5]. - 'Total product revenues- Nucynta' is estimated at$ 43.52 million, representing a decrease of 10.2% from the year-ago quarter [6]. Stock Performance - Shares of Collegium Pharmaceutical have returned -12% over the past month, compared to a -2.3% change in the Zacks S&P 500 composite [6]. - With a Zacks Rank 3 (Hold), COLL is expected to mirror overall market performance in the near future [6].